GPCR β-Arrestin Product Solutions
Universal GPCR Assays for Ligand Bias, Receptor Deorphanization, and Antagonist Discovery
With β-arrestins cell-based assays, you can easily monitor GPCR activity for antagonist mode screening, study ligand pharmacologies, and deorphanize GPCRs. Implement these assays to measure GPCR β-arrestin recruitment and subsequent internalization upon ligand or therapeutic activation of GPCRs in a dose-dependent manner.
β-Arrestins are ubiquitously expressed and function in the activation of GPCRs, desensitization of most 7-transmembrane receptors, and regulation of other signaling molecules such as protein kinases. β-Arrestin activation is part of the G protein-independent independent pathway that results from the ligand-activated GPCR phosphorylation by specific GPCR kinases referred to as GKRs. This phosphorylation leads to β-arrestin recruitment and binding that blocks G protein-mediated signaling, and results in the internalization (or endocytosis) of the GPCR; ending of the attenuation of GPCR signaling (known as desensitization). Subsequently, the GPCR is recycled back to the plasma membrane or degraded in the lysosome.
Eurofins DiscoverX® provides a complete set of analytical tools and brings decades of experience and hundreds of customer publications to β-arrestin biology. PathHunter® β-Arrestin cell lines, assays, kits, and reagents all offer a powerful and universal screening and profiling platform that can be used for virtually any Gi-, Gs-, or Gq-coupled receptor.
- Largest Portfolio – Covering ~90% of class A & B GPCR targets with over 400 cell-based assays, cell lines, kits, and reagents
- Accurate Pharmacology – Easily distinguish ligand pharmacological differences with excellent superior performance for screening antagonists, positive allosteric modulators, and partial agonists
- Multiplexing Capabilities – Run second messenger cAMP or calcium assays using the same β-arrestin cell line for ligand bias studies
- Universal System – Independent of G-protein coupling, ideal for antagonist screening and GPCR deorphanization
Assay-Ready eXpress and Bioassay Kits
- β-Arrestin eXpress and Bioassay Kits – Complete assay-ready kits with specific cell line, optimized reagents, and plates for quick Enzyme Fragment Complementation (EFC) based chemiluminescent detection. Bioassays include additional optimization for high lot-to-lot reproducibility. Choose from Known, Orphan, or Orthologs assay-ready kits.
- β-Arrestin Cell Lines – Stable cell lines confirmed for past 10 passages and rigorously and continuously validated for accurate pharmacology through Eurofins Discovery services with billions of data points screened. Choose from Known, Orphan, or Orthologs cell lines.
- Parental Cell Lines – Engineered cells to generate your own β-arrestin assays and investigate β-arrestin recruitment and GPCR desensitization and internalization of your GPCR target of interest.
- Retroviral Particles – Create target-specific, stable β-arrestin cell lines in any divided cell type. The product comes with a complete set of retroparticles and reagents combined with an easy-to-follow protocol to help you generate your own β-arrestin cell-based assays.
PathHunter β-Arrestin Assay Principle
The β-arrestin G protein-independent pathway and PathHunter GPCR β-arrestin assay principle.
– A. Ligand-induced β-arrestin (types 1 or 2) recruitment activates signaling cascades independently of G-protein signaling to provide a stoichiometric, non-amplified signal. The ligand-activated GPCR is phosphorylated by a specific GPCR kinase (GKRs, not shown here), leading to β-arrestin recruitment. This β-arrestin binding blocks G protein-mediated signaling and results in the internalization (or endocytosis) of the GPCR and ending of the attenuation of GPCR signaling (known as desensitization). Subsequently, the GPCR is recycled back to the plasma membrane or degraded in the lysosome. This stoichiometric (1 receptor: 1 ligand), non-amplified system requires full ligand occupancy of the ligand bound to the receptor to give a full signal, which lowers sensitivity to agonists, but improves the ability to detect differences of efficacy between agonists and superior sensitivity for antagonists (compared to second messenger systems). By analyzing the β-arrestin pathway, you can fine tune GPCR biology when screening antagonists as well as deorphanize GPCRs and distinguish between full, super, and partial agonists.
– B. PathHunter GPCR β-arrestin assays take advantage of DiscoverX’s proprietary Enzyme Fragment Complementation technology. The GPCR is fused in frame with a small enzyme donor fragment ProLink™ (PK) and co-expressed in cells stably expressing a fusion protein of β-arrestin and a larger, N-terminal deletion mutant of β-galactosidase (called enzyme acceptor or EA). Activation of the GPCR stimulates binding of β-arrestin to the PK-tagged GPCR and forces complementation of the two enzyme fragments, resulting in the formation of an active β-galactosidase enzyme. This interaction leads to an increase in enzyme activity that can be measured using chemiluminescent PathHunter Detection Reagents. Ultimately, β-arrestin recruitment assays offer an easy-to-use alternative to second messenger cAMP and calcium G-protein dependent pathways to enable enhanced profiles of compound pharmacology – a universal assay that expands opportunities for development of novel drugs.
Simple homogeneous protocols with no washing and a chemiluminescent output that can be read on any benchtop luminometer. Eliminate the need to load target cells before every experiment and the use of radioactivity and antibodies. Reduce the number of workflow steps to increase the efficiency of lab experimentation using the β-arrestin assays for your GPCR drug discovery needs.
- Perform multiple pathway analysis using the same cell line
- Uncover unique ligand pharmacologies
- Determine potency-based rank order of ligands
- Deorphanize GPCRs
- Evaluate GPCRs that are difficult to assay
- Compare ligand responses in different species receptors (orthologs)
- Study mutant or isoform differences
- Investigate tissue specific variations using different cell types
- Create your own GPCR β-arrestin cell-based assays in any cell type
Perform Multiple Pathway Analysis using the Same Cell Line and Uncover Unique Ligand Pharmacologies
Conveniently use only one cell line for analyzing multiple GPCR pathways and uncover unique pharmacologies for your ligand that may not have been discovered by analyzing only a single pathway.
– The β-arrestin recruitment assay (A.) followed by the second messenger (cAMP) assay (B.) were performed on the same cell line expressing human cholinergic muscarinic 2 (CHRM2) fused with the Enzyme Fragment Complementation small enzyme donor PK. Cells expressing CHRM2-PK fusion proteins were infected with PathHunter β-arrestin2 Retroparticles and tested using 3 ligands: acetylcholine, carbachol and oxotremorine-M (oxo-M). Both pathway assays showed agonist pharmacology for all 3 ligands. The β-arrestin recruitment assay in particular showed the true partial agonist pharmacology for oxo-M was revealed due to the non-amplified signal nature of the β-arrestin pathway compared to the amplified G-protein dependent pathway.
Determine Potency-Based Rank Order of Ligands
Activation and inhibition of prostaglandin D2 (CRTH2) was analyzed with 3 ligands – prostanglandin D2 (PGD2), indomethacin and ramatroban. Cells expressing CRTH2-PK fusion proteins were retrovirally infected with PathHunter β-arrestin2 Retroparticles and assayed for β-arrestin recruitment. Dose response curves showed agonist and antagonist ligand pharmacologies as well as depicted accurate potency-based rank order of the ligands.
GPR17, a Class A orphan receptor that is phylogenetically related to purinergic and CysLT receptors, has emerged as a modulator of CNS myelination. The small molecule MDL29,951 was analyzed for its ability to deorphanize GPR17 and function as a potential treatment for demyelinating CNS diseases like multiple sclerosis. CHO-K1 cells expressing the GPR17-PK fusion protein were retrovirally infected with the PathHunter β-arrestin2 Retroparticles and assayed for β-arrestin recruitment. Results indicate compound induced concentration-dependent agonist response for MDL29,951 revealing a potential modulator of GPR17 and potential therapeutic for multiple sclerosis patients.
Evaluate GPCRs that are Difficult to Assay
Lipid ligands and lysophospholipid GPCRs tend to be problematic to work with. The difficult to study GPCR lysophospholipid, EDG2 (also called LPA1 or LPAR1), was evaluated for β-arrestin recruitment using the ligand 1-Oleoyl-LPA. A CHO-K1 human EDG2-PK cell line was retrovirally infected with PathHunter β-arrestin2 Retroparticles and assayed for β-arrestin recruitment. Results revealed successful measurement of β-arrestin recruitment upon ligand stimulation and acceptable signal:background of 2.6.
Create Your Own GPCR β-arrestin Cell-Based Assays in Any Cell Type
Create your own GPCR β-arrestin cell-based assays to evaluate ligand-induced β-arrestin recruitment to any GPCR in any cell type. Using the Enzyme Fragment Complementation technology, simply infect your target cells with the PathHunter β-arrestin Retroparticles, transfect the cells with a GPCR plasmid, and perform a PathHunter GPCR β-arrestin assay with your ligand of interest. Note: β-Arrestin2-EA Retroparticles and GPCR-PK can be introduced into the target cells in either order.
An Application Note Assessing the Regulation of Mast Cell Function and its Implications in Safety Pharmacology. MrgprX2 antagonism promotes fresh…Read More
Through early discovery, screening, characterization, and particularly for market release and commercialization of biologics, drug candidates require physiologically relevant, functional…Read More
As more is learned about the intricacies of GPCR signaling, the harder it becomes to accurately describe ligand activity using…Read More
Here we show how PathHunter GPCR Internalization assays can be used to differentiate between strongly internalizing and weakly internalizing agonist…Read More
As more is learned about the intricacies of GPCR signaling, the harder it becomes to accurately describe ligand activity using…Read More
There is an increasing need to generate therapeutics targeting metabolic and gastrointestinal diseases to address the global burden of metabolic…Read More
The screening and functional characterization of novel ligands for G-protein-coupled receptors (GPCRs) remains a key activity in drug discovery process.…Read More
DiscoveRx has developed a novel application of our established Enzyme Fragment Complementation (EFC) technology that allows us to monitor protein-protein…Read More
GPCR activation results in G-protein dependent events such as second messenger signaling, as well as initiation of a host of…Read More
The pattern of intracellular signaling downstream of GPCR activation is now known to be specific to the ligand-receptor pair as…Read More
DiscoveRx has developed a panel of over 30 naturally Gq-coupled or dual coupled GPCR/Arrestin cell lines that can be used…Read More
Neutralizing antibodies (NAbs) to biological drugs may cause loss of therapeutic effi cacy and in some cases, loss of endogenous…Read More
Compounds that bind to allosteric sites offer many benefits over those which interact orthosterically. These include enhanced specificity, ability to…Read More
Mast cells are principal players in IgE-, and more recently, non-IgE-mediated anaphylactoid reactions or pseudo-allergic Adverse Drug Reactions (ADR). A…Read More
The recent appreciation of functional selectivity/ligand bias in GPCR signaling has uncovered new opportunities for therapeutic discovery and continues to…Read More
Orphan GPCRs continue to represent a target class with immense potential for the discovery of novel therapeutic compounds. In spite…Read More
DiscoveRx previously introduced a protein-protein interaction system using enzyme fragment complementation that provides a robust, HTS friendly format for monitoring…Read More
Interest in GPCR ligand bias has increased in recent years due to evidence that positive and negative aspects of drug…Read More
A common feature of 7TM receptors is that upon activation, the receptors are bound by cellular Arrestin proteins. DiscoveRx has…Read More
DiscoveRx has developed a panel of over 120 characterized GPCR cell lines that monitor receptor activity using interaction with human…Read More
DiscoveRx’s PathHunter® platform is a simple, cell-based, chemiluminescent assay format that allows for screening large numbers of small molecules or…Read More
Robust Cell-Based Assays to Identify Therapeutic Hits RapidlyRead More
Products & Custom Development Capabilities.Read More
Therapeutics targeting glucagon-like peptide, GLP-1 and GLP-2, receptors are being developed to address globally prevalent medical disorders for managing diabetes,…Watch Now
GPCRs are privileged drug targets. Approximately 100 receptors still escape from the drug discovery process as they are orphans, without…Watch Now
Opioid receptors are among the most well-known GPCRs that regulate the transmission and perception of pain. Clinical management of severe…Watch Now
This 30-minute webinar shows you how to make your own cell-based assays to analyze β-arrestin recruitment in any cell type.…Watch Now
The screening and functional characterization of novel ligands for G-Protein Coupled Receptors (GPCR) remains a key focus in drug discovery.…Watch Now
The webinar addresses the challenge that much of the GPCR druggable space remains untapped for potential therapeutic targets. To address…Watch Now
Learn about several GPCR assays and which ones to use and why for your research and drug discovery and development…Watch Now
Glucagon-like peptides, GLP-1 & GLP-2, are well-researched, metabolically significant peptide hormones secreted from the L-cells of the small intestine in…Read More
GPCRs have long been regarded as a low-hanging fruit drug target as they are conveniently located on the cell surface…Read More
Drugs interact with living physiology; an in vitro assay of drug activity can be considered a snapshot of the full…Read More
Cell-based assays are useful for understanding cellular pathways; characterizing targets and their function; identifying, screening, and optimizing ligands or drugs…Read More
Most GPCRs are pleiotropically coupled to multiple signaling pathways in cells and the availability of functional assays to separately measure…Read More
Ligand bias is the ability of compounds to exert differential signal transduction responses on activation of a GPCR. This is…Read More
β-Arrestins (βarrs) interact with G protein-coupled receptors (GPCRs) to desensitize G protein signaling, to initiate signaling on their own, and…Read More
β-Arrestins are ubiquitously expressed in all cell types, and function in the desensitization of G- protein coupled receptors (GPCRs), the…Read More
Mast cells play key roles in allergy, anaphylaxis/anaphylactoid reactions, and defense against pathogens/toxins. These cells contain cytoplasmic granules with a…Read More
The MAS-related Gq protein-coupled receptor X4 (MRGPRX4) is poorly investigated. MRGPRX4 has been proposed to be involved in pain transmission,…Read More